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Background: The current prognostication of patient survival after surgery for colorectal
liver metastases is based on clinical characteristics, but low accuracy makes it difficult to
guide treatment for the individual patient. Rapidly evolving technologies have led to the
expectation that biomarkers will be able to outperform the current clinical scoring systems
and provide more effective personalised treatment. Two main topics prevail in cancer
treatment, namely the role of the immune system and the prediction and prognostication
by application of high-throughput methodology. The aim of this review is to examine the
evidence for prognostic immunological and molecular markers studied in tumour tissue
obtained at surgical resection for colorectal liver metastases.
Methods: First we analysed immunophenotypical protein markers, that are mainly
studied by immunohistochemistry. Second, we review molecular markers by analysing
high-throughput studies on tumour mRNA and microRNA expression.
Results: CD3, CD4, and CD8 are the most frequently studied protein markers. High
intra-tumoural CD3+ T cell infiltration and low CXCR4 expression have the best
association with favourable patient survival. Studies that analysed microRNA or mRNA
expression data showed very little overlap in prognostic genes.
Conclusions: Patient prognostication after surgery for colorectal liver metastases by
analysing the immune system remains difficult. Current data are based on diverse and
heterogeneous patient populations which prohibits drawing firm conclusions.




In Europe, colorectal carcinoma (CRC) is the cancer with the third highest incidence and the
second highest mortality rate (1). The liver is the most common site of metastases, and a curative
resection of colorectal liver metastases (CRLM) is impossible in 75–80% of patients because of
widespread liver involvement, extra-hepatic disease or comorbidity (2). Although recent advances
in the treatment of CRLM have extended the possibilities to increase curability, disease will still
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recur in many patients undergoing a potentially curative
resection (3). The mean 5-year survival of patients undergoing
intentionally curative surgery varies from 15 to 60% (4).
Models that predict the outcome of treatment in patients with
CRLM can support the therapeutical management of individual
patients. To this end, several prognostic scoring systems have
been developed to guide treatment decisions, predominantly
based on clinicopathological characteristics. Unfortunately, these
clinical models still have high variability and a review of these
models found no common prognostic factor between them (5).
Multiple prognostic factors have been identified in patients with
CRLM, e.g., KRAS and BRAF mutational status and surgical
resection margin (5–7). Rapidly evolving technologies have led
to the expectation that immunological and molecular biomarkers
will be able to outperform the current clinical scoring systems and
provide more effective personalised treatment.
Objectives and Research Question
Two main topics prevail in cancer treatment, namely the role of
the immune system (8) and the prediction and prognostication
by application of high-throughput methodology. The latter has
been shown to be of great prognostic value in for instance breast
cancer (9). Both topics are not recently analysed in a systematic
review on the treatment of CRLM. Therefore, the aim of this
review is to examine the evidence for prognostic immunological
and molecular markers studied in tumour tissue obtained at
surgical resection for CRLM. To do this, we first review studies
using tissue-based immunophenotypical protein markers. We
then review tissue-based molecular markers by assessing tumour
mRNA and microRNA expression, focusing on genes related to
the immune system.
METHODS
Study Design and Search Strategy
This systematic review is based on literature that analyses
the effectiveness of tissue-based prognostic markers of patient
survival and recurrence rate after surgery for CRLM. Our
review examines papers published in English between January 1,
2005 until November 10, 2017. We chose 2005 as the starting
year because the last systematic review on prognostic markers
included papers until 2005 (10). Online publications ahead of
print were also included. The databases of Pubmed and Web
of Science were screened using the search terms: “colorectal
liver metastases” OR “colorectal liver metastasis” AND “tumour
biology” OR “tumour biology” OR “genetic” OR “genetics” OR
“molecular” OR “markers” OR “expression” OR “mutation” OR
“mirna” or “microRNA” OR “lncrna” OR “DNA” OR “RNA.”
We first screened the studies for eligibility based on title and
abstract, and then thereafter on reading the entire manuscript.
References cited in the studies were also checked to identify other
relevant papers not found in our initial search. After this initial
search process, we also performed searches on all the individual
immunological markers, e.g., using search terms like: “CD4”
AND “colorectal liver metastases.” In all instances, the data used
in this review was extracted from the original papers.
Data Collection and Analysis
The following variables were collected: immune markers, patient
survival, administration of chemotherapy, scientific method, and
statistics. Survival rates in the various studies were variable
and were recorded as median survival (in months), overall
survival (OS), cancer-specific survival (CSS) or disease-free
survival (DFS). Additionally, disease specific survival (DSS) was
recorded as CSS, and recurrence-free survival and progression-
free survival were recorded as DFS. To assess the risk of bias
in the selected studies, several study and patient characteristics
were analysed, including administration of neoadjuvant and
adjuvant chemotherapy, number of patients and the use of
univariable/multivariable analyses. However, reporting bias in
the original papers could not always be assessed, with non-
significant findings in particular not always reported. The
principal summary measures are the correlation of the immune-
related markers with patient survival. The data was analysed by
combining the results of the selected studies.
RESULTS
Study Selection
The studies examined in this review are shown in Figure 1. In
total, after removing duplicates, we identified 1,016 unique hits
using our search terms. After screening on title and abstract, we
read 150 studies in full. After reading the full paper, 14 papers
were eligible for analysis. In cited references and specific searches,
we found another 23 eligible studies, resulting in the 37 studies
that we discuss in this review (Figure 1).
Immunophenotypical Protein Markers
Phenotypes of tumour infiltrating inflammatory cells and profiles
of cytokines were mostly studied by immunohistochemistry
(IHC) on tissue sections, by scoring the presence of tumour
infiltrating lymphocytes (TILs) in the intra-tumoural and peri-
tumoural region. In contrast, studies that use tissue microarrays
(TMA) for the IHC studies only analyse intra-tumoural areas.
Distant liver parenchyma is seldom studied. The largest
proportion of TILs in the tumour microenvironment consists
of T cells, which are further subdivided according to their IHC
staining pattern. The most commonly used markers are CD3
(all T cells), CD4 (T helper cells), CD8 (cytotoxic T cells), and
FOXP3 (regulatory T cells). Supplementary Table 1 shows the
summary of all studies that analyse immune-related protein and
RNA expression.
General T Cells
In eight studies, CD3+ was used as a marker for T cells. All
eight analysed intra-tumoural expression and five also analysed
peri-tumoural regions (Table 1). An association between high
infiltration of intra-tumoural CD3+ T cells and favourable
patient survival was seen in 5/8 studies (11–15) analysing a
total of 444 patients, while the remaining three studies (16–
18), analysing 426 patients, yielded non-significant findings. The
difference in prognostic value of CD3+ seems to be associated
with neoadjuvant chemotherapy. That is, in the studies that show
an association between high intra-tumoural CD3+ T cells and
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FIGURE 1 | Selection of studies.
favourable patient survival, more patients received neoadjuvant
chemotherapy (176/235; 74.9%) (13, 15) compared to studies
that show no association with patient survival (85/270; 31.5%)
(16, 17). Five studies analysed the peri-tumoural regions (12–
15, 17), three showed no association with patient survival (13–
15), one showed a favourable DFS (17), and one showed an
unfavourable OS (12). In this latter paper, only 3 out of 36
patients had tumours with high numbers of CD3+ cells, yielding
results that are difficult to interpret (12). In addition, one study
analysed general T cells by quantification of CD45 and showed
an association between a high peri-tumoural infiltration and a
favourable survival (19).
T Helper Cells (CD4) and Cytotoxic T Cells (CD8)
Out of the eight papers that reported on CD4+ and CD8+ T
cells, six reported on both markers (11, 16–18, 20, 21) and two
Frontiers in Oncology | www.frontiersin.org 3 March 2019 | Volume 9 | Article 148
Hof et al. Review: Immune System in CRLM
TABLE 1 | Studies that analyse CD3+, CD4+, and CD8+ T cells by IHC and flow cytometry.







Brunner et al. (20) IHC 201 90* NR intra-tumoural not sign. UV (p = 0.317) not sign. UV (p = 0.713)
peri-tumourala better OS UV (p = 0.003) better OS UV (p = 0.002)
Katz et al. (16) IHC TMA 188 47* 166 intra-tumoural not sign. UV (p = 0.36) better OS
and DFS
MV (p = 0.02 &
p = 0.04)
better OS UV (p = 0.04)
MV (p = 0.08)
Nakagawa et al.
(21)
IHC 162 65* NR intra-tumoural not sign. UV (p = 0.11) not sign. UV (p = 0.48)
peri-tumoural not sign. UV (p = 0.06) not sign. UV (p = 0.10)
Katz et al. (11) IHC TMA 162 NR NR intra-tumoural better
DSS
MV (p = 0.04) worse CSS MV (p<0.001) better CSS MV (p < 0.001)
Cavnar et al. (18) IHC TMA 156 NR NR intra-tumoural not sign. UV (p = 0.9) better OS
and DFS
UV (p = 0.04
and p = 0.025)
not sign. UV (p = 0.32)
Donadon et al. (13) IHC 121 96* 64 intra-tumoural better OS MV (p =0.005)
peri-tumoural not sign. UV (p = 0.458)
Mlecnik et al. (15) IHC 114 80* 77 intra-tumoural better OS UV (p = 0.009) Better OS
and DFS
UV (p = <0.001
and p = 0.004)
peri-tumoural not sign. UV (p = 0.23) Better OS
and DFS
UV (p = 0.02
and p = 0.027)
Tanis et al. (17) IHC 82 38* 38 intra-tumoural not sign. UV (NR) not sign. UV (NR) not sign. UV (NR)
peri-tumoural better
survival
UV (p = 0.031) not sign. UV (NR) not sign. UV (NR)
Berthel et al. (12) IHC 36 NR NR intra-tumoural better OS UV (p = 0.05) better OS UV (p = 0.05)
peri-tumoural worse OS UV (p = 0.05) not sign. UV (NR)
Pugh et al. (14) Flow cy- 11 NR NR intra-tumoural better OS UV (p = 0.018)
tometry peri-tumouralb not sign. UV (p > 0.1)
N, number of patients; Neo, neoadjuvant chemotherapy administered; Adj, adjuvant chemotherapy administered; NR, not reported; UV, univariable analysis; MV, multivariable analysis.
*a certain percentage of patients in this study were administered to oxaliplatin-based neoadjuvant chemotherapeutic regimens.
a“near stroma” was noted down as peri-tumoural.
b“peri-tumoural liver” was noted down as peri-tumoural.
only on CD8 (12, 15) (Table 1). Interestingly, out of the six
papers that studied both CD4 and CD8, four described similar
associations with patient survival related to these two markers
(16, 17, 20, 21) (Table 1). An association between high intra-
tumoural infiltration of CD4+ T cells and favourable patient
survival was described in 2/6 papers (16, 18) analysing a total
of 344 patients, while three other studies analysing 544 patients
yielded non-significant results (17, 20, 21). In contrast, one
study showed an association between a high intra-tumoural CD4
expression and unfavourable patient survival (11). Additionally,
in the papers that study peri-tumoural regions (17, 20, 21), an
association between high peri-tumoural infiltration of CD4+
T cells and favourable patient survival was seen in 1/3 papers
(20). Four out of eight papers describe an association between
high intra-tumoural CD8+ T cells and a favourable patient
survival (11, 12, 15, 16), analysing a total of 500 patients, while
the other 4 studies, analysing 601 patients, observed no such
association (17, 18, 20, 21). In addition, two out of five studies
describe an association between high CD8+ T cells in the peri-
tumoural regions and favourable patient survival (15, 20), while
this association was not observed in the other three studies
(12, 17, 21) (Table 1). Of note, one study analysed granzyme B
positive immune cells by IHC, which is primarily a marker for
cytotoxic T cells, and did not find an association with patient
survival (12). Based on these papers it is tempting to suggest
that high intra-tumoural infiltration of CD4+ and CD8+ T cells
might be associated with a favourable survival, but it should be
realised that this was observed in the minority of studies (CD4:
2/6 studies; CD8: 4/8 studies). In the peri-tumoural regions, an
association with patient survival has not been observed. The
assessment of bias by chemotherapeutical treatment is limited, as
not all studies report the use of chemotherapy (Table 1).
FoxP3+ Regulatory T Cells (Tregs)
Tregs are known for their immunosuppressive function in
tumour biology. Of the four studies that fulfilled criteria for
analysis in this review, three did not show an association between
intra-tumoural FoxP3+ T cells and patient survival (16, 18, 21).
One other group also studied intra-tumoural FoxP3+ T cells,
but did not report on a survival analysis in relation to this
marker, strongly suggesting that there is no association with
patient survival (15). Contradictory results have been reported
for FoxP3+ T cells in peri-tumoural regions. While one group
showed an association between high FoxP3+ T cells and a
favourable DFS [26], this was not observed in another study (15).
Memory T cells
Memory T cells are T cells that encounter and respond to an
antigen, and are therefore primed to react much faster to a second
Frontiers in Oncology | www.frontiersin.org 4 March 2019 | Volume 9 | Article 148
Hof et al. Review: Immune System in CRLM
encounter with that antigen (22). The marker CD45RO is used to
detect memory T cells. Three independent studies did not show
an association between intra-tumoural presence of CD45RO+
T cells and patient survival (11, 15, 20). Two of these studies
also analysed the peri-tumoural regions (15, 20). In one study
analysing 201 patients by IHC, high infiltration of CD45RO+
T cells near the tumour border was associated with a favourable
patient survival (20).
CD20+ B cells
B cells are lymphocytes that can serve as antigen presenting cells,
and they are known for secreting antibodies and cytokines. The
association of CD20+ B cells with patient survival was analysed
in four independent studies. Two studies showed an association
between high peri-tumoural CD20+ B cells and a favourable
overall survival (15, 19). In addition, one of these studies also
showed an association between high intra-tumoural CD20+ B
cells and a favourable OS and DFS (15). The two other studies
observed no associations with patient survival (12, 17).
Macrophages
The innate immune system is the first line of defence against
pathogens, with macrophages as the most-studied immune cell
type in oncology, which is mainly stained using CD68 or CD163.
In one study, the presence of more intra-tumoural CD68+
cells was associated with a favourable patient DFS (18). Five
other studies reported no association between the number of
macrophages and patient survival (12, 17, 19, 23, 24). In three
out of these five studies, CD68+ (17, 24) and CD163+ (12)
macrophages are not mentioned in the survival analysis, strongly
suggesting that there is no significant association. Another study
specifically analysing the peri-tumoural regions used MAC387
as macrophage marker and found no association with patient
survival (23). MAC387 is thought to represent blood-derived
macrophages and monocytes recruited to the inflammatory site
(25). In conclusion, although there are six studies analysing
macrophages in the tumour microenvironment, only one study
found an association between favourable survival and high
CD68+macrophages.
Natural Killer (NK) cells
NK cells are a type of cytotoxic lymphocytes that belong to the
innate immune system, and they have been linked to antitumour
activity in primary CRC (26). One flow cytometry-based study
showed no association between patient survival and infiltration
of NK cells (CD56+CD3–) (14). In contrast, another study
showed that the presence of intra-tumoural NKp46+ cells was
associated with a favourable OS after multivariable analysis.
They also showed that peri-tumoural NKp46+ cells were not
associated with patient survival, suggesting that the NK cells act
intra-tumoural (13).
Mast Cells
Although mast cells are mainly known for their IgE response to
allergies, they could also be involved in primary CRC biology
(27). One study showed that high infiltration of CD117+ mast
cells in CRLM tumour tissue is associated with a favourable
DFS (17), while another study showed that high infiltration
of peri-tumoural tryptase+ mast cells is associated with an
unfavourable OS (23). In other cancers, high tumour-infiltrating
tryptase+ mast cells generally have an unfavourable association
with survival (28). The differences in markers and localisation
precludes any conclusion on the role of mast cells in CRLM.
Combining Multiple Immunophenotypical
Protein Markers
In primary colorectal cancer a semiquantitative scoring system
has been proposed, the Immunoscore, that quantifies CD3+
and CD8+ expression both intra-tumoural and peri-tumoural
(29). Moreover, several studies developed their own IHC-based
immunological score because it delivered the best explanation for
the differences in patient survival they observed in their dataset.
Three studies in CRLM showed significant associations between
a high immunoscore and favourable patient survival, two in a
univariable analysis (17, 30) and one in a multivariable analysis
(15). Turcotte et al. showed that the combination of high CD3+
T cells and high MHC class I expression was the best predictor of
long term survival (31). Another study showed that a high intra-
tumoural expression of both CD3+ T cells and NKp46+NK cells
was associated with a favourable OS (13).
Katz et al. found that the combination of intra-tumoural
CD4+ and CD8+ quantification was the best predictor of
patient survival (11). In a more recent study, the same authors
showed that a high intra-tumoural CD8+/CD3+ ratio was
associated with a favourable OS, while a high FoxP3+/CD4+
ratio and a high FoxP3+/CD8+ ratio were independently
associated with an unfavourable survival (16). Another study
showed an association between a favourable patient survival
and a high ratio of CD45RO+ cells concerning localisation
(high peri-tumoural CD45RO+ and low CD45RO+ in distant
liver parenchyma). In addition, they combine the CD45RO ratio
with the histopathological growth pattern to create their best
predictor of patient survival (20). Of note, a higher number of
peri-tumoural TILs has been reported to be associated with the
desmoplastic growth pattern of CRLM, which may explain the
relative favourable prognosis compared to the replacement or
pushing growth types (32). Finally, Mlecnik et al. show that the
combination of high CD8 and CD20 expression, in both the
intra-tumoural and peri-tumoural region, was associated with a
favourable OS and DFS (15).
Inflammatory Mediators
Cytokines and other inflammatorymediators can attract immune
cells to the site of inflammation or have a promoting or repressing
effect on the immune system. For example, CTLA-4 and PD-L1
are inhibitory ligands that can de-activate a proper T cell response
toward the tumour and are the two primary targets of modern-
day immunotherapy. One study in CRLM showed an association
between a high PD-L1 expression in the tumour stroma and a
favourable DFS (33).
CXC Chemokines and Receptors
CXCR2 is a chemokine receptor that mainly attracts neutrophils
and endothelial cells. In addition, CXCL7 is an agonist of CXCR2
and is a cleavage product that is particularly released by platelets.
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In tumourigenesis however, CXCR2 might facilitate tumour
growth and development of metastases by increased angiogenesis
(34). Desurmont et al. showed that both a high CXCR2 and
CXCL7 expression have an independent association with an
unfavourable patient survival (35). Several other chemokines
have been studied, but did not show an association with patient
survival [e.g., CXCR7/CXCL12 (33), CXCL8 (34)].
CXC Chemokine Receptor 4 (CXCR4)
CXCR4 executes its effect by binding to its ligand CXCL12
(SDF-1), allowing downstream signalling that can alter several
biological pathways including immune checkpoints (36). It has
been shown that an inhibition of CXCR4/CXCL12 can improve
the efficacy of immunotherapy, suggesting that high CXCR4
expression inhibits an effective immune response by targeting
CTLA-4 (37). Out of the six papers that study CXCR4, four show
an association between high CXCR4 expression and unfavourable
patient survival (Table 2) (33, 38–40). The two other studies
did not find significant associations with patient survival (35,
41). There is considerable variation in the methods used to
quantify protein expression by IHC, particularly in the CXCR4
studies. Studies use different cut-off values for assessing positive
staining [10% (40) vs. 50% (33)]. Another paper assessed CXCR4
expression using a digital slide computer scanner to score stromal
or cancer cells for intensity and frequency (41). Finally, a study
classified cytoplasmic CXCR4 expression as low or high relative
to the staining intensity of hepatocytes (39). These different
scoring methods and cut-off levels make it difficult to draw valid
conclusions. However, CXCR4 is associated with an unfavourable
prognosis in different scoring systems.
Monocyte Chemoattractant Protein-1 (MCP-1)/CCL2
MCP-1 is a chemokine that mainly influences monocytes and
macrophages; it can recruit macrophages via chemotaxis to
promote tumour progression (42). One study showed that
high MCP-1 expression was associated with unfavourable
patient survival and increased hepatic recurrences after surgery.
However, a significant correlation between MCP-1 and CD68+
macrophages was not found (24).
COX-2/PTGS2
COX-2 is thought to modulate prostaglandin pathways into
promoting tumour immune evasion, and could therefore be
a potential target for treatment (43). One group showed
that a high intra-tumoural COX-2 expression measured by
IHC was associated with an unfavourable OS in multivariable
analysis (41, 44).
Molecular RNA Expression Markers
Studies that analyse mRNA or miRNA expression generally
only assess intra-tumoural expression of molecular markers.
All expression studies that analyse molecular markers
initially perform a high-throughput method to scout for
interesting genes. In this review, we analysed the overlap
between the high-throughput studies to assess if the immune
system has a prominent role in identifying differences in
patient survival.
Messenger RNA Expression
Table 3 shows the results of five papers that describe gene
signatures associated with patient survival based on high-
throughput expression microarrays (45–49). Balachandran
et al. (48) used the test-set from Snoeren et al. (46) and the
validation set from Ito et al. (45), thereby creating a validated
multi-centre gene signature. Second, Snoeren et al. published
two expression studies, with the second zooming in on stage
II/III CRC patients (49). Interestingly, the four presented
individual centre gene signatures [excluding Balachandran et al.
(48)] do not share any gene and do not point toward a specific
biological pathway. Of note, because these high-throughput
studies do not show the total list of all genes and their association
with survival, there could be overlap between the studies. We
analysed the enrichment of the immune system in these five gene
signatures by selecting the 76 genes and correlated this with the
“immune system process” pathway in the Gene Ontology (GO)
database (50, 51). Ten signature genes showed overlap with all
immune related genes (BNIP3, C1ORF218, CDC2L5, COLEC11,
ITGB5, PLA2G2A, RNF135, RPS24, SERPINB1, ULBP2). By
specific searches, we found three additional genes related to
the immune system (BAT2, REG4, RIPK4). In total, 13 out of
76 (17.1%) genes were present in immune related pathways
(marked bold in Table 3), which is comparable to all known
immune related genes divided by all human genes (3119/20226;
15.4%) (50, 51). In conclusion, the presented gene signatures
based on high-throughput expression profiling generate non-
overlapping gene signatures and do not show predominant
immunological characteristics that are associated with
patient survival.
LIGHT/TNFSF14
Based on expression microarray results (45), it was validated by
IHC that both a high LIGHT expression in the tumour cells
and in TILs was associated with improved patient survival (52).
Tumour necrosis factor superfamily member 14, also known as
LIGHT, has been shown to induce T cell proliferation and tumour
regression in vivo (53).
MicroRNA Expression
MicroRNAs are small non-coding 18-22nt RNAs that function in
the post-transcriptional regulation of gene expression, primarily
by silencing mRNA (54). Table 4 shows studies included in
this review reporting on microRNAs and patient survival
(55–62). There are eight high-throughput studies, of which
seven validated their observations by qPCR (55–57, 59–62). In
addition, in the earlier described expression study of Snoeren
et al. (46), a high microRNA 103-2 expression was associated
with an unfavourable DFS (Table 3). There is little overlap
between the microRNA studies but, remarkably, the study of
Ellermeier et al. shows opposing results compared to other
studies (Table 4) (58). For example, Li et al. (59) observed
an association between a high intra-tumoural microRNA 99b-
5p expression and favourable patient survival, yet Ellermeier
et al. show an association with unfavourable patient survival
(58). Both studies differ in patient numbers and methodology
(Table 4; qPCR array vs. microarrays). In conclusion, there is no
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TABLE 2 | Studies that analyse CXCR4 expression by IHC and/or qPCR.
Author N Neo Adj Method High intra-tumour al CXCR4 expression Statistics
Yopp et al. (40) 75 NR 10 IHC unfavorable DFS MV (p = 0.006)
D’Alterio et al. (33) 33 33 33 IHC [qPCR not sign. (p = NR)] unfavorable DFS and CSS MV (p = 0.004 and p < 0.001)
Kim et al. (38) 29 0 29 qPCR (IHC NR) unfavorable OS MV (p = 0.046)
Sakai et al. (39) 92 NR NR IHC unfavorable OS MV (p = 0.027)
Goos et al. (41) 507 60 97 IHC TMA not sign. UV (p = 0.33)
Desurmont et al. (35) 55 31 0 qPCR not sign. NR
N, number of patients; Neo, neoadjuvant chemotherapy administered; Adj, adjuvant chemotherapy administered; NR, not reported; UV, univariable analysis; MV, multivariable analysis.
overlap in differentially expressed microRNAs between the eight
analysed studies.
For many microRNAs, the precise mRNA target is not
known. Three papers review microRNAs in the light of immune
responses (63), tumour attack and immune escape (64), and
PD-1/PD-L1 immune checkpoints (65), giving an overview on
the interaction between microRNAs and the immune system.
Although there is no overlap in the microRNAs that are
differentially expressed in the studies, the downstream effect
of the differentially expressed microRNAs might be similar
(Supplementary Table 2).
DISCUSSION
We have reviewed the prognostic value of tissue-based
immune-related markers after surgery for CRLM. We find
that CD3, CD4, and CD8 are the most frequently studied
protein markers (Supplementary Table 1). These T cell markers
represent the most abundant immune cell types in the tumour
microenvironment of CRLM, and are therefore logical markers
to study. However, this means that certain immune cell types
remain under-analysed in relation to patient survival. The
data generated by analysed studies are based on diverse and
heterogeneous patient populations as well as various treatment
characteristics. This prohibits drawing firm conclusions on
the role of the immune system in patients with colorectal
liver metastases. Therefore, standardising the quantification of
immune infiltration would make it easier to compare studies
with each other. In primary colorectal cancer, the consensus
Immunoscore is proposed to be implemented in the current
TNM staging. This Immunoscore quantifies CD3+ and CD8+
T cells by digital pathology software and has prognostic value
andmight contribute to compare the results among various study
groups (29).
Intra-Tumoural CD3+ T Cells
High numbers of intra-tumoural CD3, CD4, and CD8 were
predictive of a favourable patient survival. Out of the eight
studies (11, 13, 15–17, 20, 30, 31) that combined immune
markers to create the best predictor of patient survival, six
include intra-tumoural CD3+ quantification (13, 15–17, 30, 31).
These results suggest that intra-tumoural CD3+ T cells have
the best prognostic value. However, there are differences in
patient and treatment characteristics between the studies. For
example, in the studies that observed prognostic value in intra-
tumoural CD3+ quantification, neoadjuvant chemotherapy was
more often administered compared to studies that did not
observe prognostic value (74.9% vs. 31.5%). Previous studies have
shown that chemotherapeutic regimens including oxaliplatin
or anthracyclins can induce an immune response leading to
immunogenic tumour cell death (66–69). This suggests that
patients who receive these neoadjuvant treatments potentially
have more immune infiltration, e.g., due to an increase in tumour
antigen-presentation via MHC (70, 71). However, the majority
of the studies included in our review do not explain treatment
regimes in detail and do not show associations of neoadjuvant
chemotherapy with immune infiltration or patient survival.
Thus, the differences in treatment regimes of administering
neoadjuvant chemotherapy may have caused bias.
Univariable vs. Multivariable and
Clinicopathological Characteristics
Several studies only show univariable analysis of their targeted
marker without showing multivariable analysis. This makes it
difficult to estimate the importance of the targeted molecular
marker in the light of known clinicopathological risk factors. In
the studies that do find a significant association between patient
survival and an immunological marker, clinicopathological
risk factors can also be predictive of patient survival or are
strongly related to the immune marker. Out of the 10 studies
that analyse CD3/CD4/CD8/FOXP3 by IHC, six studies show
multivariable analyses including clinicopathological variables
(11, 13, 15, 16, 18, 21). Out of those six studies, four
show that known clinical risk factors are also independent
predictors of patient survival (11, 16, 18, 21). For example,
Katz et al. show by multivariable analysis that high intra-
tumoural CD3 expression is associated with a favourable
patient survival, but so is the clinical risk score (72). In fact,
the clinical risk score is an even better predictor of patient
survival compared to high intra-tumoural CD3 expression [p
< 0.001; odds ratio 8.8 (3.3–23.5) vs. p = 0.04; odds ratio 4.2
(1.1–16.9)] (11).
Other Molecular Prognostic Markers
Multiple additional molecular markers have shown prognostic
value after surgical resection of colorectal liver metastases.
It is known that mutations in the KRAS (codon 12 and 13)
and BRAF (V600E) genes are associated with unfavourable
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TABLE 3 | High-throughput studies of mRNA expression.
Studies Ito et al. (45) Snoeren et al. (46) Snoeren et al. (49) Balachandran et al.
(48)
Van der Stok et
al. (47)
Nr of patients 96 119 30 96 test [Ito et al. (45)] 63
(only CRC stage II/III) 119 validation [Snoeren
et al. (42)]






















Neoadjuvant chemo 72% In DFS ≤ 1 year: 62.5% In DFS < 6
months: 29.4%
See Ito et al. (45) and
Snoeren (46)
In DFS ≤ 1 year: 0%
In DFS > 1 year: 40.4% In DFS > 24
months: 15.4%
In DFS > 3 year: 0%
Adjuvant chemo 82% In DFS ≤ 1 year: 45.8% In DFS < 6
months: 94.1%
See Ito et al. (45) and
Snoeren (46)
In DFS ≤ 1 year: 0%
In DFS > 1 year: 74.5% In DFS > 24
months: 53.8%
In DFS > 3 year: 0%
Genes present in BAG3 BAT2 AMPD1 CES2 CASS4
signature C1ORF218 C6orf141 ARL6IP5 DKK1 CLRN3
C1ORF71 CCDC85A ASAP2 DNAJC12 COX6A1
CDC2L5 CPLX1 BNIP3 FGFBP1 ERN1
CHN2 FAM174B C13orf3 HOXC6 G3BP2
CKS2 FRMD6 COLEC11 LRP8 ITGB5
FGFBP1 GPR143 FYTTD1 LRRC42 JARID1A
FLJ39632 hsa-mir-103-2 GDF15 NUP62CL KIAA0319
HSGT1 ITSN1 GTF3C3 ODC1 RAD9A
LRRC42 KIAA0562 LAPTM4A PLA2G2A RPUSD1
PCBD1 MAPKAPK2 LYPLAL1 PLCB4 ULBP2
PLCB4 MYNN SERPINB5 RAD23B
RAD23B OR5P2 SMYD2 RBBP8









Five studies report on high-throughput mRNA expression. We report on the number of patients, the experimental method and protocol, and the statistical method. Furthermore, we
report the percentage of patients in the different experimental patient groups that received neoadjuvant and/or adjuvant chemotherapy. Finally, we show the presented gene signatures
that predict patient survival in these four different studies. Genes related to the immune system are in bold and italics.
patient survival (7). In addition, several molecular characteristics
are positively associated with an enhanced immune response
in (metastatic) colorectal cancer and favourable patient
survival (73), like the CpG island methylator phenotype
(CIMP) (74) and the microsatellite instability phenotype
(75). Patients with microsatellite instable tumours typically
have less often metastases, a better survival and a good
response to modern immunotherapy (76). Although we
primarily studied immune related markers on protein and
RNA level, alterations at the DNA level, not discussed
in this review, could potentially also be relevant for
prognostication (7).
Applicability as Prognostic Biomarker
Modern high-throughput methods like next generation
sequencing or microarrays are innovative, but not every
hospital has the equipment and knowledge to apply them in
a diagnostic setting. Thus, although IHC is a relatively old
technology, it is the most used method to predict patient
survival. The high-throughput studies of both mRNA and
miRNA in CRLM find little overlap in prioritising genes. In
contrast, gene signatures designed by high-throughput methods
are used to guide treatment decisions in breast cancer: this
signature (MammaPrint) is based on the expression of 70
genes and is used to assess whether patients could benefit from
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TABLE 4 | High-throughput studies on microRNAs.
Author Nr of
patients






Kahlert et al. (55) 30 18 16 microarray –> qPCR In tumour invasion fronta: let-7 In liver invasion front b: 19b and
194
Pizzini et al. (56) 46 NR NR microarray –> qPCR 10b
Manceau et al. (57) 132 132 NR microarray –> qPCR 31-3p
Ellermeier et al. (58) 27 NR NR qPCR array 9 125a-5p, 145, 199a-5p,
323-3p, 99b
Li et al. (59) 48 22 NR microarray –> qPCR 99b-5p
Pecqeux et al. (60) 25 NR NR microarray –> qPCR In adjacent liver: 125, 127, 145, 192,
194, 199-5, 215, 429
In stroma CRLM: 199-3
Kingham et al. (61) 91 53 58 NGS –> qPCR 203
Li et al. (62) 48 NR NR microarray –> qPCR 196b-5p
Eight studies analysed microRNA expression by high-throughput methods. The microRNAs showed in bold italics are differentially expressed in more than one study. Neo, neoadjuvant
chemotherapy administered; Adj, adjuvant chemotherapy administered; NR, not reported.
aTumour invasion front = first 10 cell rows into the tumour measured from the tumour/liver transition border.
bLiver invasion front = first 10 cell rows into the liver measured from the tumour/liver transition border.
adjuvant chemotherapy (77). One could speculate whether
high-throughput studies are worthwhile, since genetic markers
have the problem that there are potentially many markers. Thus,
you need to build up a catalogue of all possible genetic markers,
which takes time and cohorts of sufficient size. In contrast,
every patient has an immune response (whether effective or




The most important IHC-marker for prognostication in the
studies we reviewed is CD3, a general T cell marker. Although
intra-tumoural CD3+ quantification is the best immune-related
predictor of patient survival, we think that this marker is
not accurate enough to guide individual treatment decisions.
In addition, while high-throughput expression studies show
promise, there is no consensus yet about the important
genes for prognostication. A high CXCR4 expression was
reported by several studies as an unfavourable prognostic
factor, and this might be a future target for improving
the efficacy of immunotherapy (37). We know that patients
with immunocompetent tumours can potentially benefit from
immunotherapy (78, 79). Hopefully, future therapy can enhance
the function of the immune system in an effective way to
eradicate cancer in all tumour-bearing organs.
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